Found: 8
Select item for more details and to access through your institution.
Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 3, p. 181, doi. 10.1002/ajh.23898
- By:
- Publication type:
- Article
Beyond Andromeda: Improving Therapy for Light Chain Amyloidosis.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2020.624573
- By:
- Publication type:
- Article
Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2019, v. 145, n. 6, p. 1527, doi. 10.1007/s00432-019-02927-x
- By:
- Publication type:
- Article
Progressive Multifocal Leukoencephalopathy: a rare infectious complication following allogeneic hematopoietic cell transplantation ( HCT).
- Published in:
- European Journal of Haematology, 2014, v. 92, n. 1, p. 83, doi. 10.1111/ejh.12208
- By:
- Publication type:
- Article
Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide‐based maintenance therapy.
- Published in:
- British Journal of Haematology, 2021, v. 193, n. 3, p. e23, doi. 10.1111/bjh.17393
- By:
- Publication type:
- Article
The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
- Published in:
- British Journal of Haematology, 2013, v. 162, n. 5, p. 657, doi. 10.1111/bjh.12452
- By:
- Publication type:
- Article
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
The absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles is not significantly impacted by the use of myeloid growth factors and predicts clinical outcomes in classical Hodgkin lymphoma regardless of their use.
- Published in:
- Blood & Lymphatic Cancer: Targets & Therapy, 2014, v. 4, p. 39, doi. 10.2147/BLCTT.S66114
- By:
- Publication type:
- Article